Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
Revenue growth masks deteriorating profitability: operating margins trend lower (64% lower past two years) as Zynex accelerates hiring in face of early signs of reimbursement pressure. Tricare becomes first large health plan since Medicare to drop ZYXI’s device for one of its largest indications citing poor efficacy - we expect other payors to follow Zynex…
Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
Zynex Medical Products, Non-Invasive Pain Management
Newsbriefs Journal of Nuclear Medicine
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial - The Lancet
Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
Zynex: Abusive Pricing Model Unsustainable (NASDAQ:ZYXI)
Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research
ZYXI: A case study - by Adu Subramanian
Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States
Zynex: Turnaround Nears End – UnitedHealthcare Cuts TENS Reimbursement (ZYXI)
